Cargando…

Knockdown of Serine–Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells

The pre-mRNA splicing regulator serine–arginine protein kinase 1 (SRPK1), a member of the SR kinase family, plays an essential role in cancer development and various pathophysiological processes. However, its expression pattern and functions in renal cell carcinoma (RCC) remain unknown. Therefore, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xingtao, Yang, Jinjian, Jia, Zhankui, Wei, Pengtao, Zhang, Han, Lv, Wenwei, Sun, Jiantao, Huo, Qingxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841233/
https://www.ncbi.nlm.nih.gov/pubmed/27662590
http://dx.doi.org/10.3727/096504016X14743324568129
Descripción
Sumario:The pre-mRNA splicing regulator serine–arginine protein kinase 1 (SRPK1), a member of the SR kinase family, plays an essential role in cancer development and various pathophysiological processes. However, its expression pattern and functions in renal cell carcinoma (RCC) remain unknown. Therefore, the aim of this study was to assess the role of SRPK1 in RCC. Our data showed that SRPK1 was significantly upregulated in human RCC tissues and cell lines. SRPK1 interference significantly inhibited the proliferation of RCC cells and inhibited tumor growth in vivo. In addition, SRPK1 interference also suppressed migration and invasion in RCC cells. A mechanistic study showed that SRPK1 interference inhibited the phosphorylation of PI3K and Akt in RCC cells. In conclusion, our findings suggest that SRPK1 interference inhibits the growth and invasion of RCC cells through suppressing the PI3K/Akt signaling pathway. Thus, SRPK1 might be a therapeutic target for the treatment of RCC.